Search

Your search keyword '"Schliemann, C."' showing total 254 results
Start Over Author "Schliemann, C."
254 results on '"Schliemann, C."'

4. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

Author

Krug, U, Berdel, W E, Gale, R P, Haferlach, C, Schnittger, S, Müller-Tidow, C, Braess, J, Spiekermann, K, Staib, P, Beelen, D, Serve, H, Schliemann, C, Stelljes, M, Balleisen, L, Maschmeyer, G, Grüneisen, A, Eimermacher, H, Giagounidis, A, Rasche, H, Hehlmann, R, Lengfelder, E, Thiel, E, Reichle, A, Aul, C, Ludwig, W-D, Kern, W, Haferlach, T, Köpcke, W, Görlich, D, Sauerland, M C, Heinecke, A, Wörmann, B J, Hiddemann, W, and Büchner, T

Published
2016
Full Text
View/download PDF

5. Multiparametrische MRT-Bildgebung zur unmittelbaren Evaluation der Wirkungsweise einer Therapie mit dem CD13 – gerichteten Gewebefaktor tTF-NGR in Patienten mit fortgeschrittenen soliden Tumoren

Author

Gerwing, M, additional, Krähling, T, additional, Schliemann, C, additional, Schwöppe, C, additional, Klein, S, additional, Berdel, F A, additional, Hartmann, W, additional, Heindel, L W, additional, Berdel, W, additional, and Wildgruber, M, additional

Published
2022
Full Text
View/download PDF

6. P545: CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND TRISOMY 19

Author

Kayser, S., primary, Martínez-Cuadrón, D., additional, Rodriguez-Veiga, R., additional, Hänel, M., additional, Tormo, M., additional, Schäfer-Eckart, K., additional, Botella, C., additional, Stölzel, F., additional, Bernal del Castillo, T., additional, Keller, U., additional, Rodriguez-Medina, C., additional, Held, G., additional, Amigo, M.-L., additional, Schliemann, C., additional, Colorado, M., additional, Kaufmann, M., additional, Barrios Garcia, M., additional, Krause, S. W., additional, Görner, M., additional, Jost, E., additional, Steffen, B., additional, Ho, A. D., additional, Baldus, C., additional, Serve, H., additional, Platzbecker, U., additional, Müller-Tidow, C., additional, Thiede, C., additional, Bornhäuser, M., additional, Montesinos, P., additional, Röllig, C., additional, and Schlenk, R. F., additional

Published
2022
Full Text
View/download PDF

7. P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD123-POSITIVE AML

Author

Daver, N. G., primary, Montesinos, P., additional, Aribi, A., additional, Martinelli, G., additional, Altman, J., additional, Roboz, G., additional, Wang, E. S., additional, Burke, P. W., additional, Jeyakumar, D., additional, Walter, R. B., additional, DeAngelo, D. J., additional, Erba, H. P., additional, Advani, A., additional, Gastaud, L., additional, Thomas, X., additional, Todisco, E., additional, Pemmaraju, N., additional, Mendez, L., additional, de la Fuente, A., additional, Gaidano, G., additional, Curti, A., additional, Boissel, N., additional, Recher, C., additional, Schliemann, C., additional, Vyas, P., additional, Sloss, C. M., additional, Wang, J., additional, Malcolm, K. A., additional, Zweidler-McKay, P. A., additional, and Sweet, K. L., additional

Published
2022
Full Text
View/download PDF

8. P478: THE GERMLINE VARIANT GFI1-36N PROMOTES GENETIC INSTABILITY IN LEUKEMIC CELLS AND OPENS NEW THERAPEUTIC APPROACHES FOR ABOUT 15% OF ALL AML PATIENTS

Author

Vorwerk, J., primary, Frank, D., additional, Sun, K., additional, Neumannn, F., additional, Heuser, M., additional, Kunadt, D., additional, Berdel, W. E., additional, Mikesch, J.-H., additional, Schliemann, C., additional, Lenz, G., additional, Jayavelu, A. K., additional, and Khandanpour, C., additional

Published
2022
Full Text
View/download PDF

10. 1554TiP A randomized phase II study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced or metastatic soft tissue sarcoma

Author

Kessler, T., primary, Pink, D., additional, Reichardt, P., additional, Palmerini, E., additional, Stacchiotti, S., additional, Grignani, G., additional, Rutkowski, P., additional, Hemmerle, T., additional, Neri, D., additional, and Schliemann, C., additional

Published
2021
Full Text
View/download PDF

11. 1553TiP A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma

Author

Schliemann, C., primary, Pink, D., additional, Flörcken, A., additional, Ahrens, M., additional, Egerer, G., additional, Götze, K., additional, Palmerini, E., additional, Stacchiotti, S., additional, Grignani, G., additional, Rutkowski, P., additional, Ullrich, R., additional, Strapatsas, J., additional, Hemmerle, T., additional, Neri, D., additional, and Kessler, T., additional

Published
2021
Full Text
View/download PDF

12. A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma

Author

Schliemann, C., Pink, D., Floercken, A., Ahrens, M., Egerer, G., Goetze, K., Palmerini, E., Stacchiotti, S., Grignani, G., Rutkowski, P., Ullrich, R., Strapatsas, J., Hemmerle, T., Neri, D., Kessler, T., Schliemann, C., Pink, D., Floercken, A., Ahrens, M., Egerer, G., Goetze, K., Palmerini, E., Stacchiotti, S., Grignani, G., Rutkowski, P., Ullrich, R., Strapatsas, J., Hemmerle, T., Neri, D., and Kessler, T.

Published
2021

19. 563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study

Author

Schliemann, C., primary, Gerwing, M., additional, Heinzow, H., additional, Harrach, S., additional, Schwöppe, C., additional, Wildgruber, M., additional, Hansmeier, A., additional, Angenendt, L., additional, Berdel, A.F., additional, Kessler, T., additional, Wilms, C., additional, Hartmann, W., additional, Wardelmann, E., additional, Kraehling, T., additional, Heindel, W., additional, Gerss, J., additional, Schmidt, H., additional, Lenz, G., additional, Mesters, R., additional, and Berdel, W.E., additional

Published
2020
Full Text
View/download PDF

22. Adjuvant chemotherapy—Radiotherapy—Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases

Author

Schliemann, C. (Christoph), Kerkhoff, A. (Andrea), Hesse, P. (Paula), Bröckling, S. (Sebastian), Hardes, J. (Jendrik), Streitbürger, A. (Arne), Andreou, D. (Dimosthenis), Gosheger, G. (Georg), Elges, S. (Sandra), Wardelmann, E. (Eva), Hartmann, W. (Wolfgang), Mesters, R.M. (Rolf), Lenz, G. (Georg), Willich, N. (Normann), Kriz, J. (Jan), Eich, H. (Hans-Theodor), Berdel, W.E. (Wolfgang), Keßler, T. (Torsten), and Universitäts- und Landesbibliothek Münster

Subjects
Medicine and health, ddc:610
Abstract

Adjuvant therapy of local soft tissue sarcomas (STS) after wide surgical excision still is a topic under controversial scientific debate. In this single center report we have offered an adjuvant “sandwich” therapy protocol consisting of 4 cycles of doxorubicin (75 mg/m2 i.v. over 1 h on day 1) followed by ifosfamide (5 g/m2 i.v. over 24 h starting on day 1) and local radiotherapy scheduled between chemotherapy cycles 2 and 3 to 104 consecutive patients after wide surgical excision (R0) of histologically proven high-grade STS. After a mean follow-up of 39 months (range 5–194 months) relapse free survival (RFS) at 2 and 5 years was 68.1% (95% CI, 58.5–77.7%) and 61.2% (95% CI, 50.4–71.6%). When analyzing the 82 STS cases of the extremities only 2- and 5-year RFS was 74.0% (95% CI, 64.0–84.0%) and 65.3% (95% CI, 53.7–76.9%). By intent-to-treat analysis, the overall survival (OS) at 2 years was 87.3% (95% CI, 80.5–94.1%) and 75.6% (95% CI, 65.2–86.0%) at 5 years, while OS for STS of the extremities only cohort was 90.5% (95% CI, 83.7–97.3%) and 79.0% (95% CI, 68.4–89.6%), respectively. Tolerability of the treatment was good. This analysis demonstrates the feasibility of adjuvant chemoradiotherapy and reflects the results of the long lasting intensive multidisciplinary team approach at our “high-volume” sarcoma center. The long-term survival in our patients is among the highest reported and the low local and distant recurrence rate in high-risk STS is at least comparable to the published data.

Published
2019

23. Selective Inactivation of Cancer Drugs by SAMHD1 Provides a Molecular Rationale for Therapeutic Stratification in AML

Author

Schneider, C., Oellerich, T., Knecht, K.M., Thomas, D., Buzovetsky, O., Schliemann, C., Bohnenberger, H., Angenendt, L., Hartmann, W., Wardelmann, E., Scheich, S., Comoglio, F., Wilke, A., Ströbel, P., Serve, H., Geisslinger, G., Keppler, O.T., Xiong, Y., Cinatl, J., and Publica

Abstract

Background: Nucleoside analog (NA) drugs are widely used to treat a variety of cancers, including acute myeloid leukemia (AML). With an essential role in regulating the cellular dNTP pool by degrading cellular nucleotides, SAMHD1 has the potential to decrease the cellular concentration of frequently prescribed NAs and thereby diminish their clinical efficacy in cancer therapy. Method: In this study, we used biochemical, structural, and cell based methods to examine the interaction of SAMHD1 with various AML cancer drugs, including cytarabine, cladribine, clofarabine, fludarabine, gemcitabine and the two DNA-hypomethylating agents (HMAs) decitabine and azacytidine. Results: We found that both the catalytic and the allosteric sites of SAMHD1 can bind NAs and that the SAMHD1 substrate specificity is regulated by 2' sugar modifications of the nucleotide analogs. Cell culture, AML blasts and xenotransplantation models confirmed the crystallography findings that most of these drugs are affected by SAMHD1 activity, while some stay unaffected. In accordance with these data expression levels of SAMHD1 are correlating with survival parameters in patients treated with SAMHD1-dependent NAs. Conclusion: Taken together, these results establish SAMHD1 as a substrate-specific resistance factor that has promise as a predictive biomarker for drug stratification and a therapeutic target in nucleoside analog-based AML therapy. Conflict of interest: none

Published
2019

24. Randomized comparison of 90 mg versus 60 mg daunorubicin in 7+3 standard induction for newly diagnosed acute myeloid leukemia : Results from the SAL-DaunoDouble trial

Author

Röllig, C., Steffen, B., Herbst, R., Noppeney, Richard, Racil, Z., Schäfer-Eckart, K., Krämer, A., Neubauer, A., Baldus, C. D., Schliemann, C., Kaufmann, M., Mertova, J., Jost, E., Niemann, D., Novak, J., Krause, S. W., Scholl, S., Held, G., Parmentier, S., Szotkowski, T., Zak, P., Rank, A., Wass, M., Buske, S., Platzbecker, U., Kramer, M., Schetelig, J., Müller-Tidow, C., Serve, H., Bornhäuser, M., Berdel, W. E., Mayer, J., Ehninger, G., and Studienallianz Leukämie (SAL)

Subjects
Medizin
Published
2018

25. Cardiac toxicity of two anthracycline doses in AML induction : Short term results from the randomized SAL-DaunoDouble trial

Author

Dendorfer, S., Kramer, M., Schmidt-Brücken, K., Stölzel, F., Herbst, R., Noppeney, Richard, Racil, Z., Mayer, J., Steffen, B., Bochtler, T., Krämer, A., Müller-Tidow, C., Schäfer-Eckart, K., Burchert, A., Neubauer, A., Baldus, C. D., Schliemann, C., Kaufmann, M., Jost, E., Naumann, R., Scholl, S., Hochhaus, A., Ehninger, G., Bornhäuser, M., and Röllig, C.

Subjects
Medizin
Published
2018

26. Allogeneic hematopoietic stem cell transplantation (HSCT) beyond first complete remission (CR) in patients with acute myeloid leukemia (AML) : Results from the AMLCG1999 trial

Author

Evers, G., Beelen, Dietrich W., Braess, J., Sauerland, Maria Cristina, Kolb, H. J., Reichle, A., Holler, E., Schwerdtfeger, R., Arnold, R., Scheid, C., Krug, U., Müller-Tidow, C., Schliemann, C., Mikesch, J.-H., Lenz, G., Wörmann, B. J., Hiddemann, W., Berdel, W. E., and Stelljes, M.

Subjects
Medizin
Published
2018

27. SAMHD1 HD domain bound to decitabine triphosphate

Author

Oellerich, T., primary, Schneider, C., additional, Thomas, D., additional, Knecht, K.M., additional, Buzovetsky, O., additional, Kaderali, L., additional, Schliemann, C., additional, Bohnenberger, H., additional, Angenendt, L., additional, Hartmann, W., additional, Wardelmann, E., additional, Rothenburger, T., additional, Mohr, S., additional, Scheich, S., additional, Comoglio, F., additional, Wilke, A., additional, Strobel, P., additional, Serve, H., additional, Michaelis, M., additional, Ferreiros, N., additional, Geisslinger, G., additional, Xiong, Y., additional, Keppler, O.T., additional, and Cinatl, J., additional

Published
2019
Full Text
View/download PDF

28. PS1033 A PROOF OF CONCEPT OF LSD1-INHIBITON IN A PHASE I/II PILOT TRIAL OF TCP AND ATRA IN REFRACTORY / RELAPSED AML PATIENTS NOT ELIGIBLE FOR INTENSIVE THERAPY

Author

Wass, M., primary, Schlenk, R.F., additional, Göthert, J., additional, Noppeney, R., additional, Schliemann, C., additional, Mikesch, J.-H., additional, Dugas, M., additional, Wermke, M., additional, Röllig, C., additional, Bornhäuser, M., additional, Serve, H., additional, Binder, M., additional, Müller, L.P., additional, Göllner, S., additional, Pabst, C., additional, and Müller-Tidow, C., additional

Published
2019
Full Text
View/download PDF

29. S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA

Author

Angenendt, L., primary, Röllig, C., additional, Montesinos, P., additional, Martínez-Cuadrón, D., additional, Barragan, E., additional, García, R., additional, Botella, C., additional, Martínez, P., additional, Ravandi, F., additional, Kadia, T., additional, Kantarjian, H.M., additional, Cortes, J., additional, Juliusson, G., additional, Lazarevic, V., additional, Höglund, M., additional, Lehmann, S., additional, Recher, C., additional, Pigneux, A., additional, Bertoli, S., additional, Dumas, P.-Y., additional, Dombret, H., additional, Preudhomme, C., additional, Micol, J.-B., additional, Terré, C., additional, Ráčil, Z., additional, Novák, J., additional, Žák, P., additional, Wei, A.H., additional, Tiong, I.S., additional, Wall, M., additional, Estey, E., additional, Shaw, C., additional, Exeler, R., additional, Wagenführ, L., additional, Stölzel, F., additional, Thiede, C., additional, Stelljes, M., additional, Lenz, G., additional, Mikesch, J.-H., additional, Serve, H., additional, Ehninger, G., additional, Berdel, W.E., additional, Kramer, M., additional, Krug, U., additional, and Schliemann, C., additional

Published
2019
Full Text
View/download PDF

30. CD13-targetierte vaskuläre Infarzierung als experimentelle Therapie beim kleinzelligen Lungenkarzinom

Author

Schmidt, LH, additional, Stucke-Ring, J, additional, Brand, C, additional, Schliemann, C, additional, Harrach, S, additional, Muley, T, additional, Herpel, E, additional, Kessler, T, additional, Mohr, M, additional, Görlich, D, additional, Kreuter, M, additional, Lenz, G, additional, Wardelmann, E, additional, Thomas, M, additional, Schwoeppe, C, additional, Hartmann, W, additional, and Berdel, W, additional

Published
2018
Full Text
View/download PDF

31. Die Bedeutung des Prostata-spezifischen Membranantigens (PSMA) im nicht-kleinzelligen Lungenkarzinom

Author

Schmidt, LH, additional, Heitkoetter, B, additional, Schulze, AB, additional, Schliemann, C, additional, Konrad, S, additional, Trautmann, M, additional, Marra, A, additional, Hillejan, L, additional, Mohr, M, additional, Evers, G, additional, Wardelmann, E, additional, Rahbar, K, additional, Görlich, D, additional, Lenz, G, additional, Berdel, W, additional, Hartmann, W, additional, Wiewrodt, R, additional, and Huss, S, additional

Published
2018
Full Text
View/download PDF

32. Thoracic Malignancies and Pulmonary Nodules in Patients under Evaluation for Transcatheter Aortic Valve Implantation (TAVI): Incidence, Follow Up and Possible Impact on Treatment Decision

Author

Schmidt, L.H. (Lars), Vietmeier, B. (Benedikt), Kaleschke, G.T. (Gerrit), Schülke, C. (Christoph), Görlich, D. (Dennis), Schliemann, C. (Christoph), Keßler, T. (Torsten), Schulze, A.B. (Arik), Buerke, B.T. (Boris), Kümmel, A. (Andreas), Thrull, M. (Michael), Wiewrodt, R.G. (Rainer), Baumgartner, H. (Helmut), Berdel, W.E. (Wolfgang), Mohr, M. (Michael), and Universitäts- und Landesbibliothek Münster

Subjects
Medicine and health, ddc:610
Abstract

BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become the treatment of choice in patients with severe aortic valve stenosis who are not eligible for operative replacement and an alternative for those with high surgical risk. Due to high age and smoking history in a high proportion of TAVI patients, suspicious findings are frequently observed in pre-procedural chest computer tomography (CCT). METHODS: CCT scans of 484 consecutive patients undergoing TAVI were evaluated for incidentally discovered solitary pulmonary nodules (SPN). RESULTS: In the entire study population, SPN ≥ 5 mm were found in 87 patients (18%). These patients were compared to 150 patients who were incidentally collected from the 397 patients without SPN or with SPN < 5 mm (control group). After a median follow-up of 455 days, lung cancer was diagnosed in only two patients. Neither SPN ≥ 5 mm (p = 0.579) nor SPN > 8 mm (p = 0.328) were significant predictors of overall survival. CONCLUSIONS: Despite the high prevalence of SPNs in this single center TAVI cohort lung cancer incidence at midterm follow-up seems to be low. Thus, aggressive diagnostic approaches for incidentally discovered SPN during TAVI evaluation should not delay the treatment of aortic stenosis. Unless advanced thoracic malignancy is obvious, the well documented reduction of morbidity and mortality by TAVI outweighs potentially harmful delays regarding further diagnostics. Standard guideline-approved procedure for SPN can be safely performed after TAVI.

Published
2016

33. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Author

Schmidt, L.H. (Lars), Kümmel, A. (Andreas), Görlich, D. (Dennis), Mohr, M. (Michael), Bröckling, S. (Sebastian), Mikesch, J. (Jan-Henrik), Grünewald, I. (Inga), Marra, A. (Alessandro), Schultheis, A.M. (Anne), Müller-Tidow, C. (Carsten), Spieker, G.T. (Georg), Schliemann, C. (Christoph), Berdel, W.E. (Wolfgang), Wiewrodt, R.G. (Rainer), Hartmann, W. (Wolfgang), and Universitäts- und Landesbibliothek Münster

Subjects
Medicine and health, ddc:610
Abstract

Background: Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However, in lung cancer the diagnostic, prognostic and predictive value of these immunologic factors remains unclear. Method: The impact of both factors was evaluated in a study collective of 321 clinically well-annotated patients with non-small lung cancer (NSCLC) using immunohistochemistry. Results: PD-1 expression by tumor infiltrating lymphocytes (TILs) was found in 22%, whereas tumor cell associated PD-L1 expression was observed in 24% of the NSCLC tumors. In Fisher’s exact test a positive correlation was found for PD-L1 and Bcl-xl protein expression (p = 0.013). Interestingly, PD-L1 expression on tumor cells was associated with improved overall survival in pulmonary squamous cell carcinomas (SCC, p = 0.042, log rank test), with adjuvant therapy (p = 0.017), with increased tumor size (pT2-4, p = 0.039) and with positive lymph node status (pN1-3, p = 0.010). These observations were confirmed by multivariate cox regression models. Conclusion: One major finding of our study is the identification of a prognostic implication of PD-L1 in subsets of NSCLC patients with pulmonary SCC, with increased tumor size, with a positive lymph node status and NSCLC patients who received adjuvant therapies. This study provides first data for immune-context related risk stratification of NSCLC patients. Further studies are necessary both to confirm this observation and to evaluate the predictive value of PD-1 and PD-L1 in NSCLC in the context of PD-1 inhibition.

Published
2015

34. An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia

Author

Angenendt, L, primary, Reuter, S, additional, Kentrup, D, additional, Benk, A S, additional, Neumann, F, additional, Hüve, J, additional, Martens, A C, additional, Schwöppe, C, additional, Kessler, T, additional, Schmidt, L H, additional, Sauer, T, additional, Brand, C, additional, Mikesch, J-H, additional, Lenz, G, additional, Mesters, R M, additional, Müller-Tidow, C, additional, Hartmann, W, additional, Wardelmann, E, additional, Neri, D, additional, Berdel, W E, additional, Roesli, C, additional, and Schliemann, C, additional

Published
2017
Full Text
View/download PDF

37. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

Author

Krug, U., Berdel, W. E., Gale, R. P., Haferlach, C., Schnittger, S., Mueller-Tidow, C., Braess, J., Spiekermann, K., Staib, P., Beelen, D., Serve, H., Schliemann, C., Stelljes, M., Balleisen, L., Maschmeyer, G., Grueneisen, A., Eimermacher, H., Giagounidis, A., Rasche, H., Hehlmann, R., Lengfelder, E., Thiel, E., Reichle, A., Aul, C., Ludwig, W-D, Kern, W., Haferlach, T., Koepcke, W., Goerlich, D., Sauerland, M. C., Heinecke, A., Woermann, B. J., Hiddemann, W., Buechner, T., Krug, U., Berdel, W. E., Gale, R. P., Haferlach, C., Schnittger, S., Mueller-Tidow, C., Braess, J., Spiekermann, K., Staib, P., Beelen, D., Serve, H., Schliemann, C., Stelljes, M., Balleisen, L., Maschmeyer, G., Grueneisen, A., Eimermacher, H., Giagounidis, A., Rasche, H., Hehlmann, R., Lengfelder, E., Thiel, E., Reichle, A., Aul, C., Ludwig, W-D, Kern, W., Haferlach, T., Koepcke, W., Goerlich, D., Sauerland, M. C., Heinecke, A., Woermann, B. J., Hiddemann, W., and Buechner, T.

Abstract

We randomized 3375 adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome to test whether increasingly intensive chemotherapies assigned at study-entry and analyzed on an intent-to-treat basis improved outcomes. In total, 1529 subjects <60 years were randomized to receive: (1) a first course of induction therapy with high-dose cytarabine and mitoxantrone (HAM) or with standard-dose cytarabine, daunorubicin and 6-thioguanine (TAD) followed by a second course of HAM; (2) granulocyte-colony stimulating factor (G-CSF) or no G-CSF before induction and consolidation courses; and (3) high-dose therapy and an autotransplant or maintenance chemotherapy. In total, 1846 subjects. 60 years were randomized to receive: (1) a first induction course of HAM or TAD and second induction course of HAM (if they had bone marrow blasts >= 5% after the first course); and (2) G-CSF or no G-CSF as above. Median follow-up was 7.4 years (range, 1 day to 14.7 years). Five-year event-free survivals (EFSs) for subjects receiving a first induction course of HAM vs TAD were 17% (95% confidence interval, 15, 18%) vs 16% (95% confidence interval 14, 18%; P = 0.719). Five-year EFSs for subjects randomized to receive or not receive G-CSF were 19% (95% confidence interval 16, 21%) vs 16% (95% confidence interval 14, 19%; P = 0.266). Five-year relapse-free survivals (RFSs) for subjects <60 years receiving an autotransplant vs maintenance therapy were 43% (95% confidence interval 40, 47%) vs 40 (95% confidence interval 35, 44%; P = 0.535). Many subjects never achieved pre-specified landmarks and consequently did not receive their assigned therapies. These data indicate the limited impact of more intensive therapies on outcomes of adults with AML. Moreover, none of the more intensive therapies we tested improved 5-year EFS, RFS or any other outcomes.

Published
2016

38. PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

Author

Albring, J C, primary, Inselmann, S, additional, Sauer, T, additional, Schliemann, C, additional, Altvater, B, additional, Kailayangiri, S, additional, Rössig, C, additional, Hartmann, W, additional, Knorrenschild, J R, additional, Sohlbach, K, additional, Groth, C, additional, Lohoff, M, additional, Neubauer, A, additional, Berdel, W E, additional, Burchert, A, additional, and Stelljes, M, additional

Published
2016
Full Text
View/download PDF

39. Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center

Author

Pohlen, M., primary, Marx, J., additional, Mellmann, A., additional, Becker, K., additional, Mesters, R. M., additional, Mikesch, J.-H., additional, Schliemann, C., additional, Lenz, G., additional, Muller-Tidow, C., additional, Buchner, T., additional, Krug, U., additional, Stelljes, M., additional, Karch, H., additional, Peters, G., additional, Gerth, H. U., additional, Gorlich, D., additional, and Berdel, W. E., additional

Published
2016
Full Text
View/download PDF

40. Inzidenz und Bedeutung pulmonaler Rundherde unter TAVI-Patienten

Author

Schmidt, LH, primary, Vietmeier, B, additional, Kaleschke, G, additional, Görlich, D, additional, Schliemann, C, additional, Bröckling, S, additional, Wiewrodt, R, additional, Bürke, B, additional, Baumgartner, H, additional, Schülke, C, additional, Berdel, W, additional, and Mohr, M, additional

Published
2016
Full Text
View/download PDF

41. Die prognostische Wertigkeit der Expression von PD1 und PDL1 im nicht kleinzelligen Lugenkarzinom

Author

Schmidt, LH, primary, Kümmel, A, additional, Görlich, D, additional, Mohr, M, additional, Bröckling, S, additional, Mikesch, JH, additional, Gruenewald, I, additional, Marra, A, additional, Schultheis, A, additional, Wardelmann, E, additional, Müller-Tidow, C, additional, Spieker, T, additional, Schliemann, C, additional, Berdel, W, additional, Wiewrodt, R, additional, and Hartmann, W, additional

Published
2016
Full Text
View/download PDF

42. Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC

Author

Schmidt, L.H., primary, Kuemmel, A., additional, Schliemann, C., additional, Schulze, A., additional, Humberg, J., additional, Mohr, M., additional, Görlich, D., additional, Hartmann, W., additional, Bröckling, S., additional, Marra, A., additional, Hillejan, L., additional, Goletz, S., additional, Karsten, U., additional, Berdel, W.E., additional, Spieker, T., additional, and Wiewrodt, R., additional

Published
2016
Full Text
View/download PDF

46. Expression der Angiopoietine und ihres Rezeptors Tie-2 im Knochenmark von Patienten mit akuter myeloischer Leukämie

Author

Schliemann, C. (Christoph), Mesters, R.M. (Rolf), and Universitäts- und Landesbibliothek Münster

Subjects
AML, Angiopoietin, Tie-2, Immunhistochemie, Angiogenese, Mikrogefäßdichte, Medicine and health, ddc:610
Abstract

Die Angiopoietine und ihr Rezeptor Tie-2 spielen eine zentrale Rolle in der Angiogenese solider Tumoren. Ihre Bedeutung für die Angiogenese der AML ist unklar. Wir untersuchten die Expression von Ang-1, Ang-2 und Tie-2 im Knochenmark von AML-Patienten und Kontrollpersonen mittels APAAP-Immunhistochemie. Die Expression von Ang-2 und Tie-2 war im Knochenmark der AML-Patienten signifikant höher als bei Kontrollpersonen. Ang-1 wurde dagegen in beiden Kollektiven gleich stark exprimiert, so dass die Ratio der Ang-2- zu Ang-1-Expression im Knochenmark der AML-Patienten deutlich zugunsten von Ang-2 verschoben war. Sowohl die Ang-2-Expression als auch die Ang-2/Ang-1 Ratio korrelierten mit der Mikrogefäßdichte im Gesamtkollektiv. Der Umschlag der Angiopoietin-Balance könnte eine entscheidende Bedeutung für die AML-induzierte Neovaskularisation haben. Damit wäre das Tie-2/Angiopoietin-System möglicherweise ein geeigneter Angriffspunkt antiangiogener Therapiestrategien in der Behandlung der AML.

Published
2005

47. An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia

Author

Angenendt, L, Reuter, S, Kentrup, D, Benk, A S, Neumann, F, Hüve, J, Martens, A C, Schwöppe, C, Kessler, T, Schmidt, L H, Sauer, T, Brand, C, Mikesch, J-H, Lenz, G, Mesters, R M, Müller-Tidow, C, Hartmann, W, Wardelmann, E, Neri, D, Berdel, W E, Roesli, C, and Schliemann, C

Abstract

The concept of arming antibodies with bioactive payloads for a site-specific therapy of cancer has gained considerable interest in recent years. However, a successful antibody-based targeting approach critically relies on the availability of a tumor-associated target that is not only preferentially expressed in the tumor tissue but is also easily accessible for antibody therapeutics coming from the bloodstream. Here, we perfused the vasculature of healthy and acute myeloid leukemia (AML)-bearing rats with a reactive ester derivative of biotin and subsequently quantified the biotinylated proteins to identify AML-associated bone marrow (BM) antigens accessible from the bloodstream. In total, >1400 proteins were identified. Overall, 181 proteins were >100-fold overexpressed in AML as compared with normal BM. Eleven of the most differentially expressed proteins were further validated by immunohistochemistry and confocal microscopic analyses, including novel antigens highly expressed in AML cells (for example, adaptor-related protein complex 3 β2) and in the leukemia-modified extracellular matrix (ECM) (for example, collagen-VI-α-1). The presented atlas of targetable AML-associated BM proteins provides a valuable basis for the development of monoclonal antibodies that could be used as carriers for a site-specific pharmacodelivery of cytotoxic drugs, cytokines or radionuclides to the BM in AML.

Published
2018
Full Text
View/download PDF

48. Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients

Author

Liersch, R. (Ruediger), Gerss, J. (Joachim), Schliemann, C. (Christoph), Bayer, T. (T.), Schwöppe, C. (Christian), Biermann, F. (Frank), Appelmann, I. (Iris), Kessler, T.A. (Torsten), Löwenberg, B. (Bob), Büchner, T. (Thomas), Hiddemann, W. (Wolfgang), Müller-Tidow, C. (Carsten), Berdel, W.E. (Wolfgang), Mesters, I. (Ilse), Liersch, R. (Ruediger), Gerss, J. (Joachim), Schliemann, C. (Christoph), Bayer, T. (T.), Schwöppe, C. (Christian), Biermann, F. (Frank), Appelmann, I. (Iris), Kessler, T.A. (Torsten), Löwenberg, B. (Bob), Büchner, T. (Thomas), Hiddemann, W. (Wolfgang), Müller-Tidow, C. (Carsten), Berdel, W.E. (Wolfgang), and Mesters, I. (Ilse)

Abstract

Osteopontin (OPN) is a glycoprotein that is secreted by osteoblasts and hematopoietic cells. OPN suppresses the proliferation of hematopoietic stem cells in vitro and may regulate the hematopoietic stem cell pool. Increased serum OPN concentrations occur in chronic myeloid leukemia, multiple myeloma, and acute myeloid leukemia (AML). In the present study, we analyzed the prognostic impact of OPN in AML by investigating the expression and relevance of OPN in newly diagnosed AML patients from 2 large study groups (the German AML Cooperative Group and the Dutch-Belgian Hematology Oncology Cooperative group). IHC (n = 84), ELISAs of blood/BM sera (n = 41), and microarray data for mRNA levels (n = 261) were performed. Expression of OPN protein was increased in AML patients both in BM blasts (IHC) and in BM serum (ELISA) compared with healthy controls. Patients expressing high levels of OPN within the BM (IHC) experienced shortened overall survival (OS; P = .025). Multivariate analysis identified karyotype, blast clearance (day 16), and the level of OPN expression as independent prognostic factors for OS. This prompted us to analyze microarray data from 261 patients from a third cohort. The analysis confirmed OPN as a prognostic marker. In summary, high OPN mRNA expression indicated decreased eventfree survival (P = .0002) and OS (P = .001). The prognostic role of OPN was most prominent in intermediate-risk AML. These data provide evidence that OPN expression is an independent prognostic factor in AML.

Published
2012
Full Text
View/download PDF

49. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies

Author

Pedretti, M, Rancic, Z, Soltermann, A, Herzog, B A, Schliemann, C, Lachat, Mario, Neri, D, Kaufmann, P A, Pedretti, M, Rancic, Z, Soltermann, A, Herzog, B A, Schliemann, C, Lachat, Mario, Neri, D, and Kaufmann, P A

Abstract

OBJECTIVE: F16, F8 and L19 are three fully human monoclonal antibodies, specific to splice isoforms of tenascin-C and fibronectin, which stain sites of active tissue remodeling and which are currently in Phase I and II clinical trials as radio-immunoconjugates and immunocytokines in patients with cancer and arthritis. The characterization of atherosclerosis using these antibodies may open novel pharmacodelivery options for the imaging and treatment of cardiovascular conditions. It may also allow a better assessment of the corresponding immunoconjugates in polymorbid patients with atherosclerotic plaques. METHODS: We performed a comparative immunohistochemical analysis with the F16, F8 and L19 antibodies in 28 freshly frozen human carotid plaques and in 11 normal arteries. Furthermore, we assessed the localization of the antibodies in relation to the infiltrating macrophages, vasa vasorum and Ki67-positive proliferating cells of the plaque. RESULTS: The F16 antibody, specific to the extra-domain A1 of tenascin-C, stained plaques with a selective and intense pattern, while F8 and L19, specific to the EDA and EDB domains of fibronectin, respectively, exhibited a less selective and intense staining. In immunofluorescence, F16 was found to bind regions rich in macrophages, vasa vasorum and proliferating cells, while showing no detectable vs. weak staining of normal arteries and of quiescent plaque structures. CONCLUSION: The human monoclonal antibody F16 stains areas of active tissue remodeling in atherosclerotic plaques and may thus deserve to be investigated as a suitable building block for the development of radiopharmaceuticals for plaque imaging or for the antibody-based targeted delivery of therapeutic agents to atherosclerotic lesions.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results